Büttner T, Kuhn W, Müller T, Patzold T, Przuntek H
Department of Neurology, Ruhr-University Bochum, St. Josef-Hospital, Bochum, Germany.
Clin Neuropharmacol. 1995 Oct;18(5):458-63. doi: 10.1097/00002826-199510000-00009.
In recent studies, disorders of chromatic and achromatic vision in parkinsonian patients have been demonstrated; these could be partially restored after application of L-Dopa. In this study, the effect of a 3-day infusion therapy with amantadine sulphate on color vision was evaluated in 19 parkinsonian patients by use of the Farnsworth-Munsell 100-Hue test. Under this treatment, the motor symptoms of parkinsonism improved significantly as assessed by the part "motor examination" of the Unified Parkinson's Disease Rating Scale (UPDRS). However, the total error scores of the Farnsworth-Munsell 100-Hue test before and after amantadine sulphate infusions were unchanged [before therapy, 94.53 (SD = 52.09); after therapy, 99.5 (SD = 58.81)]. From these results, it can be concluded that the pathophysiology of dopaminergic pathways in the visual system differs from that of the basal ganglia.
最近的研究表明，帕金森病患者存在色觉和非色觉障碍；应用左旋多巴后这些障碍可部分恢复。在本研究中，通过使用法恩斯沃思-芒塞尔100色调试验，对19例帕金森病患者评估了硫酸金刚烷胺3天输注疗法对色觉的影响。在这种治疗下，根据统一帕金森病评定量表（UPDRS）的“运动检查”部分评估，帕金森病的运动症状有显著改善。然而，硫酸金刚烷胺输注前后法恩斯沃思-芒塞尔100色调试验的总误差评分没有变化[治疗前，94.53（标准差=52.09）；治疗后，99.5（标准差=58.81）]。从这些结果可以得出结论，视觉系统中多巴胺能通路的病理生理学与基底神经节不同。
